Avalo Therapeutics
AVTX
36 hedge funds and large institutions have $39.1M invested in Avalo Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
6% more funds holding
Funds holding: 34 → 36 (+2)
4.93% less ownership
Funds ownership: 77.37% → 72.44% (-4.9%)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
41% less capital invested
Capital invested by funds: $66.1M → $39.1M (-$27M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.87M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$444K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$442K |
| 4 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$201K |
| 5 |
BlackRock
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.78M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.37M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$769K |
| 4 |
AI
Allostery Investments
Stamford,
Connecticut
|
-$458K |
| 5 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$242K |
AVTX Hedge Fund Activity: Q2 2025 in Review
36 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2025, worth a combined $39.1M — down 41% from $66.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AVTX positions and 2 closed out — a net gain of 2 holders — while 9 added to existing stakes and 12 trimmed.
The largest buyer was Bank of America, adding an estimated $1.87M. The largest seller was Perceptive Advisors, cutting an estimated $1.78M.
- 36 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2025, up from 34 in Q1 2025.
- Funds reported $39.1M of Avalo Therapeutics stock for Q2 2025, down 41% quarter-over-quarter.
- 4 funds opened new Avalo Therapeutics positions in Q2 2025 and 2 closed out, a net change of +2 holders.
- The largest Avalo Therapeutics buyer in Q2 2025 was Bank of America, an estimated $1.87M added.
- The largest Avalo Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $1.78M sold.
Based on aggregated 13F filings for Q2 2025.